Osimertinib Recruiting Phase 2 Trials for Recurrent Non-Small Cell Lung Carcinoma / Metastatic Malignant Neoplasm in the Brain / EGFR Activating Mutation / Lung Non-Small Cell Carcinoma / EGFR NP_005219.2:p.T790M / Non-Small Cell Lung Carcinoma (NSCLC) / Lung Carcinoma Metastatic in the Brain Treatment